what is microdosing semaglutide One Size Does Not Fit All: Understanding for Diabetes in Multidose Pens Microdosing GLP-1s Is Gaining Popularity—But

The trial, conducted across multiple international sites and involving 725 adults living with obesity or overweight but without type 2 diabetes, concluded in April 2026 after 76 weeks of treatment

A, Theander S, Rubi B, Chaffard G, Wollheim CB, et al

[DOI] [PMC free article] [PubMed] [Google Scholar] 13.Adverse drug reactions of GLP-1 agonists: a systematic review of case reports

Supply Kits ($25$50): Syringes, alcohol swabs, and sharps containers may be billed separately from the medication

What can we conclude To date, we have not seen robust reports that persons with obesity or overweight taking GLP-1 medications experience greater SMM loss than persons with obesity or overweight taking non-GLP-1 medications (after controlling for greater total weight loss)